All biotech stocks are volatile. I would still maintain, that genomic stocks are MORE volatile WITHOUT major news items that drive the ups and downs. Case study, TEMPUS for the last six months. starts at 40, up to 70, down to 50, up to 80, down to 35, up to 50. Six-month range, $23 to $80 (about 4x).
###
###
In the same period, Biogen has moved 2X (range $140, $250).
In the same period, Thermo Fisher has moved in a 20% range ($600, $500, $600)
